Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world

被引：0
|
作者：
Sugisaka, J. [1 ]
Sugawara, S. [1 ]
Toi, Y. [1 ]
Ogasawara, T. [1 ]
Aso, M. [1 ]
Tsurumi, K. [1 ]
Ono, K. [1 ]
Shimizu, H. [1 ]
Domeki, Y. [1 ]
Aiba, T. [1 ]
Kawana, S. [1 ]
Saito, R. [1 ]
Terayama, K. [1 ]
Kawashima, Y. [1 ]
Nakamura, A. [1 ]
Yamanda, S. [1 ]
Kimura, Y. [1 ]
Honda, Y. [1 ]
机构：
[1] Sendai Kousei Hosp, Dept Pulm Med, Sendai, Miyagi, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
336P
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Pembrolizumab monotherapy for advanced/recurrent non-small cell lung cancer: a Greater Manchester experience
    Tivey, A.
    Wu, K. S.
    Tay, R.
    Gomes, F.
    Taylor, P.
    Blackhall, F.
    Summers, Y.
    Califano, R.
    Cove-Smith, L.
    LUNG CANCER, 2019, 127 : S45 - S46
  • [42] COST EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB MONOTHERAPY IN ADVANCED PD-L1 ≥50% NON-SMALL CELL LUNG CANCER (NSCLC) IN THE IRISH SETTING
    Chu, R.
    Vegas, A.
    Gorry, C.
    Power, D.
    VALUE IN HEALTH, 2022, 25 (01) : S61 - S61
  • [43] First-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥ 50%) advanced non-small cell lung cancer (aNSCLC) in the real world: A national French bispective multicentric cohort-ESCKEYP trial (GFPC 05-2018).
    Descourt, Renaud
    Greillier, Laurent
    Perol, Maurice
    Ricordel, Charles
    Auliac, Jean-Bernard
    Falchero, Lionel
    Demontrond, Pierre
    Veillon, Remi
    Vieillot, Sabine
    Guisier, Florian
    Marcq, Marie
    Justeau, Gregoire
    Game, Laurence Bigay
    Bernardi, Marie
    Fournel, Pierre
    Doubre, Helene
    Pinsolle, Julian
    Amrane, Karim
    Chouaid, Christos
    Decroisette, Chantal
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
    Xiong, Anwen
    Wang, Lei
    Chen, Jianhua
    Wu, Lin
    Liu, Baogang
    Yao, Jun
    Zhong, Hua
    Li, Jie
    Cheng, Ying
    Sun, Yulan
    Ge, Hui
    Yao, Jifang
    Shi, Qin
    Zhou, Ming
    Chen, Bolin
    Han, Zhengxiang
    Wang, Jinliang
    Bu, Qing
    Zhao, Yanqiu
    Chen, Junqiang
    Nie, Ligong
    Li, Gaofeng
    Li, Xingya
    Yu, Xinmin
    Ji, Yinghua
    Sun, Daqiang
    Ai, Xiaohong
    Chu, Qian
    Lin, Yu
    Hao, Jiqing
    Huang, Dingzhi
    Zhou, Chengzhi
    Shan, Jinlu
    Yang, Hongzhong
    Liu, Xuewen
    Wang, Jing
    Shang, Yanhong
    Mei, Xiaodong
    Yang, Jie
    Lu, Dongmei
    Hu, Mingxiu
    Wang, Zhongmin Maxwell
    Li, Baiyong
    Xia, Michelle
    Zhou, Caicun
    LANCET, 2025, 405 (10481): : 839 - 849
  • [45] Cost-Minimization Analysis of Pembrolizumab Monotherapy Versus Nivolumab in Combination with Ipilimumab as First-Line Treatment for Metastatic PD-L1-Positive Non-small Cell Lung Cancer: A US Payer Perspective
    Qiao, Nan
    Insinga, Ralph
    Burke, Thomas
    Lopes, Gilberto
    PHARMACOECONOMICS-OPEN, 2021, 5 (04) : 765 - 778
  • [46] Dramatic Response of a PD-L1-Positive Advanced Angiosarcoma of the Scalp to Pembrolizumab
    Hamacher, Rainer
    Kaempfe, Dietrich
    Reuter-Jessen, Kirsten
    Poettgen, Christoph
    Podleska, Lars E.
    Farzaliyev, Farhad
    Steinau, Hans-Ulrich
    Schuler, Martin
    Schildhaus, Hans-Ulrich
    Bauer, Sebastian
    JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 7
  • [47] Immunological Characterization of PD-L1-Positive Non-Small Cell Lung Cancer Cells
    Igarashi, Tomoyuki
    Hanaoka, Jun
    Teramoto, Koji
    Daigo, Yataro
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S600 - S600
  • [48] Cost-Minimization Analysis of Pembrolizumab Monotherapy Versus Nivolumab in Combination with Ipilimumab as First-Line Treatment for Metastatic PD-L1-Positive Non-small Cell Lung Cancer: A US Payer Perspective
    Nan Qiao
    Ralph Insinga
    Thomas Burke
    Gilberto Lopes
    PharmacoEconomics - Open, 2021, 5 : 765 - 778
  • [49] Real-world versus clinical trial outcomes of pembrolizumab plus chemotherapy in patients with stage IV non-squamous non-small cell lung cancer
    Verschueren, M.
    Kruik, V.
    Peters, B.
    Bloem, L.
    Bijsmans, A. R.
    Egberts, T.
    van de Garde, E.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S72 - S72
  • [50] Real-World Efficacy of First-Line Pembrolizumab in Patients with Advanced PD-L1 High Non-Small Cell Lung Cancer in Argentina
    Kuzminin, A.
    Minatta, N.
    Bluthgen, M.
    Rizzo, M.
    Naveira, M.
    Wainsztein, V.
    Lupinacci, L.
    Rizzi, M.
    Faura, M.
    Perfetti, A.
    Recondo, G., Jr.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S589 - S590
12345